XOMA XOMA Corporation: חוב להון עצמי

The XOMA (XOMA) price chart demonstrates the impact of ethical biomedical asset selection, with the separate_debt_total_eq metric standing at 1.07. The absence of debt neutralizes financial threats, although payment timelines remain dependent on regulators. The business's profitability relies on licensing fees and royalties that XOMA generates through collaborations with pharmaceutical behemoths.

This metric reflects the extent of the company's reliance on borrowed funds relative to its equity. The ratio is calculated as total liabilities divided by net assets, measuring financial leverage and bankruptcy risk. By analyzing changes in the business's leverage ratio, an investor can track debt load dynamics in real time. The asset-light model of XOMA (XOMA), featuring passive royalty income, minimizes the need for loans. This ensures low indebtedness and high capital resilience.